$Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) Is a Safe and Effective Treatment Option for Older Patients with Relapsed or Refractory Low-Grade Non-Hodgkin’s Lymphoma (NHL)$

Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) Is a Safe and Effective Treatment Option for Older Patients with Relapsed or Refractory Low-Grade Non-Hodgkin’s Lymphoma (NHL)

R. Meredith; R.J. Schilder; C. Emmanouilides; K. Vo; T.E. Witzig; I.W. Flinn; M. Darif; L.I. Gordon; A. Molina

作者R. Meredith; R.J. Schilder; C. Emmanouilides; K. Vo; T.E. Witzig; I.W. Flinn; M. Darif; L.I. Gordon; A. Molina
卷第63卷
印刷ISSN0360-3016
文件大小175.46KB
发表时间2005
DOI10.1016/j.ijrobp.2005.07.715

发现好书期刊，享受阅读乐趣

Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) Is a Safe and Effective Treatment Option for Older Patients with Relapsed or Refractory Low-Grade Non-Hodgkin’s Lymphoma (NHL)